| Literature DB >> 22405520 |
Liana C Del Gobbo1, Yiqing Song, Paul Poirier, Eric Dewailly, Ronald J Elin, Grace M Egeland.
Abstract
BACKGROUND: Premature ventricular complexes (PVC) predict cardiovascular mortality among several adult populations. Increased arrhythmia prevalence has been reported during controlled magnesium (Mg) depletion studies in adults. We thus hypothesized that serum magnesium (sMg) concentrations are inversely associated with the prevalence of PVC in adults at high cardiovascular risk.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22405520 PMCID: PMC3337820 DOI: 10.1186/1475-2840-11-23
Source DB: PubMed Journal: Cardiovasc Diabetol ISSN: 1475-2840 Impact factor: 9.951
Medical chart review of adults (≥ 18 yrs) of the general Cree population (n = 750)
| Ischemia/infarction | 2 |
|---|---|
| Cardiac insufficiency | 4 |
| Atrial fibrillation | 3 |
| Ventricular arrhythmia/tachycardia | 5 |
| Bradycardia | 3 |
| Ventricular hypertrophy | 2 |
| Angina | 6 |
| Hypertension (diagnosed) | 185 |
| (BP > 130/85 mmHg, or treatment of diagnosed) | 249 |
| Ischemic heart disease | 6 |
| Diseases of the pulmonary circulation | 3 |
| Stroke | 4 |
| Cerebrovascular diseases | 11 |
| Diseases of arteries, arterioles or capillaries | 6 |
| Metabolic syndrome | 352 |
| (excluding diagnosed type 2 diabetics/FG ≥ 7 mmol/L) | 140 |
| Gestational diabetes (history of) | 23 |
| Type 1 diabetes | 1 |
| Type 2 diabetes (diagnosed) | 140 |
| (diagnosed or FG ≥ 7 mmol/L) | 176 |
| Antiplatelet | 6 |
| Antihypertensives | 183 |
| Diuretics (specifically) | 62 |
| Cholesterol-lowering drugs | 79 |
| Statins (specifically) | 73 |
| Multivitamins | 41 |
| Mg supplements | 8 |
| Post-menopausal | 104 |
| Hormone replacement therapy | 1 |
| Oral contraceptives | 92 |
| Currently breastfeeding | 35 |
| Kidney disease | 13 |
| Cancer | 6 |
Characteristics of Cree adults (≥ 18 yrs) according to PVC prevalence during Holter electrocardiogram (n = 750)
| Characteristic | No PVC | 1-6 PVC/hr | > 6 PVC/hr |
|---|---|---|---|
| Sex | |||
| 217 (37%) | 64 (54%) | 28 (68%) | |
| 374 (63%) | 54 (46%) | 13 (32%)*** | |
| Age (yrs) | |||
| 194 (33%) | 23 (19%) | 5 (12%) | |
| 302 (51%) | 44 (37%) | 14 (34%) | |
| 95 (16%) | 51 (43%) | 22 (54%)*** | |
| BMI (kg/m2) | |||
| 170 (29%) | 36 (31%) | 8 (20%) | |
| 421 (71%) | 82 (69%) | 33 (80%) | |
| Smoking | |||
| 329 (56%) | 40 (34%) | 16 (39%) | |
| 204 (34%) | 61 (52%) | 21 (51%) | |
| 58 (10%) | 17 (14%) | 4 (10%)*** | |
| Alcohol1 | |||
| 271 (46%) | 48 (41%) | 10 (24%) | |
| 312 (54%) | 69 (59%) | 31 (76%)** | |
| Exercise | |||
| 187 (32%) | 37 (31%) | 13 (32%) | |
| 217 (36%) | 32 (27%) | 10 (24%) | |
| 187 (32%) | 49 (42%) | 18 (44%)** | |
| Hypertension | 153 (26%) | 41 (35%) | 15 (37%)* |
| CVD history1 | 18 (3%) | 7 (6%) | 4 (10%)** |
| MetS2 | 95 (16%) | 30 (25%) | 15 (37%)*** |
| Diabetes3 | 122 (21%) | 37 (31%) | 17 (41%)*** |
*p < 0.01 **p < 0.05 ***p < 0.001
1 Includes history of cardiovascular events/arrhythmia or CVD, excludes hypertensives
2 Excludes diagnosed type 2 diabetics/FG ≥ 7 mmol/L
3 Includes diagnosed type 2 diabetes or FG ≥ 7 mmol/L
Figure 1PVC prevalence (%) during 2-hr Holters among adults (n = 750) according to sMg concentrations (mmol/L). Legend: CVD excluded (grey bars) omits individuals with cardiovascular event history or conditions. Difference in PVC prevalence among participants with sMg ≤ 0.70 vs. > 0.70 mmol/L among all adults (blue bars): p = 0.015; for CVD excluded (grey bars): p = 0.07.
Adjusted odds ratios & 95% confidence intervals for presence of ≥ 1 PVC on 2-hr Holters across the sMg concentration range (n = 750)
| sMg | ≤ 0.7 | 0.71-0.80 | 0.81-0.90 | > 0.90 |
|---|---|---|---|---|
| Model 1 | 1.00 | 0.26 (0.07-0.88) | 0.27 (0.08-0.93) | 0.22 (0.06-0.81) |
| Model 2 | 1.00 | 0.25 (0.07-0.85) | 0.26 (0.08-0.88) | 0.19 (0.05-0.71) |
| Model 3 | 1.00 | 0.25 (0.07-0.85) | 0.26 (0.08-0.88) | 0.20 (0.05-0.73) |
| Model 4 | 1.00 | 0.24 (0.07-0.86) | 0.25 (0.07-0.92) | 0.19 (0.05-0.77) |
| Model 5 | 1.00 | 0.24 (0.07-0.87) | 0.26 (0.07-0.93) | 0.18 (0.04-0.73) |
Model 1: adjusted for age and sex
Model 2: additionally adjusted for region and BMI
Model 3: additionally adjusted for smoking, physical activity, alcohol consumption
Model 4: additionally adjusted for history of cardiovascular events/disease, type 2 diabetes, kidney disease, antihypertensive and cholesterol lowering drug use
Model 5: additionally adjusted for blood DHA
Figure 2PVC prevalence (%) during 2-hr Holters among adults without CVD (n = 652) by sMg concentrations (mmol/L) and diabetic status. Legend: PVC prevalence declined with sMg concentration in adults with T2DM (blue bars) only (p < 0.001 for trend), even when hypomagnesemic adults were excluded (p = 0.005 for trend). While no nondiabetic (grey bars) had PVC during monitoring, only 1% of nondiabetics were hypomagnesemic (sMg ≤ 0.70 mmol/L)
Effect of hypomagnesaemia in type 2 diabetics without CVD history on adjusted odds ratios & 95% confidence intervals for ≥ 1 PVC on 2-hr Holters (n = 149)
| Type 2 diabetics | Type 2 diabetics | |
|---|---|---|
| Model 1 | 1.00 | 0.28 (0.08-0.98) |
| Model 2 | 1.00 | 0.25 (0.07-0.92) |
| Model 3 | 1.00 | 0.26 (0.07-1.04) |
| Model 4 | 1.00 | 0.25 (0.06-1.03) |
| Model 5 | 1.00 | 0.24 (0.06-0.98) |
Model 1: adjusted for age and sex
Model 2: additionally adjusted for region and BMI
Model 3: additionally adjusted for smoking, physical activity, alcohol consumption
Model 4: additionally adjusted for kidney disease, antihypertensive and cholesterol lowering drug use
Model 5: additionally adjusted for blood DHA